Pityriasis Rubra Pilaris, Refractory to IL-17A Inhibition, With Rapid Improvement Following IL-17A IL-17F Blockade by Bimekizumab. J of Skin 2024, 8 (6), 1987-1992. https://doi.org/10.25251/skin.8.6.13.